Regeneron Pharmaceuticals is a biotechnology company. Co.'s products include: EYLEA, which is designed for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma and retinopathy of prematurity; Dupixent, which is designed for the treatment of atopic dermatitis, asthma, rhinosinusitis with nasal polyposis, eosinophilic esophagitis (in adults and adolescents) and prurigo nodularis; and Libtayo, which is designed for the treatment of metastatic or locally advanced first-line non-small cell lung cancer and metastatic or recurrent second-line cervical cancer. The REGN stock yearly return is shown above.
The yearly return on the REGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the REGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|